Thomas Thomas Net Worth

The estimated Net Worth of Thomas T. Thomas is at least $246 Tisíc dollars as of 21 September 2021. Mr. Thomas owns over 3,834 units of Opiant Pharmaceuticals Inc stock worth over $229,422 and over the last 5 years he sold OPNT stock worth over $16,220. In addition, he makes $0 as Director at Opiant Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Thomas OPNT stock SEC Form 4 insiders trading

Thomas has made over 5 trades of the Opiant Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,834 units of OPNT stock worth $38,340 on 21 September 2021.

The largest trade he's ever made was exercising 3,834 units of Opiant Pharmaceuticals Inc stock on 21 September 2021 worth over $38,340. On average, Thomas trades about 1,233 units every 38 days since 2019. As of 21 September 2021 he still owns at least 11,110 units of Opiant Pharmaceuticals Inc stock.

You can see the complete history of Mr. Thomas stock trades at the bottom of the page.

Thomas Thomas biography

Thomas T. Thomas serves as Director of the Company. Mr. Thomas has over 25 years of financial experience in biotechnology, packaged goods, financial services and non-profit organizations. Since 2011, Mr. Thomas has been self-employed providing financial, investment and risk management consulting services to a variety of technology, beverage and food and biotechnology companies. In 2009, Mr. Thomas joined the Stupski Foundation (“Stupski”), as its chief financial officer. In 2010, Mr. Thomas was promoted to chief operating officer and served as Stupski’s interim chief executive officer before leaving Stupski in late 2010 to pursue consulting opportunities. Prior to joining Stupski, Mr. Thomas spent 12 years at Genentech, Inc. (“Genentech”), serving as the company’s corporate treasurer from 2001 to 2006. His executive responsibilities at Genentech included treasury operations, cash and investment management, corporate finance, global procurement, enterprise risk management, business continuity and real estate finance and administration. From 1990 to 1994, Mr. Thomas was a manager of financial strategy with Del Monte Foods and he began his career in 1988 at GE Capital Corporation (“GE”) as an analyst in GE’s corporate finance group, which focused on leveraged buyouts and bankruptcy financing. Mr. Thomas currently serves on the board of trustees of the Cancer Prevention Institute of California and has previously served on the boards of the San Francisco Security Analysts and Hospitality House. He is also a mentor in the Ivy Exec Mentorship Network. Mr. Thomas is a Chartered Financial Analyst and received his Master of Business Administration from the University of Cincinnati, where he was a Graduate Fellow, and a Bachelor of Music from the University of Cincinnati’s College-Conservatory of Music.

What's Thomas Thomas's mailing address?

Thomas's mailing address filed with the SEC is C/O OPIANT PHARMACEUTICALS, INC., 233 WILSHIRE BLVD. SUITE 400, SANTA MONICA, CA, 90401.

Insiders trading at Opiant Pharmaceuticals Inc

Over the last 21 years, insiders at Opiant Pharmaceuticals Inc have traded over $16,027,532 worth of Opiant Pharmaceuticals Inc stock and bought 199,545 units worth $2,080,156 . The most active insiders traders include Craig A Collard, Marc A Cohen a Alain J Cohen. On average, Opiant Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $159,046. The most recent stock trade was executed by Roger Crystal on 27 January 2023, trading 1,358 units of OPNT stock currently worth $27,513.

What does Opiant Pharmaceuticals Inc do?

Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

Complete history of Mr. Thomas stock trades at Opiant Pharmaceuticals Inc

Opiant Pharmaceuticals Inc executives and stock owners

Opiant Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Roger Crystal,
  President, Chief Executive Officer, Director
• Michael Sinclair,
  Executive Chairman of the Board
• Dr. Roger Crystal,
  Pres, CEO & Director
• Dr. Phil Skolnick D.Sc. (hon), Ph.D.,
  Chief Scientific Officer
• David D. O'Toole,
  Chief Financial Officer
• Michael Porter,
  IR Contact Officer
• Richard Daly,
  Independent Director
• Craig Collard,
  Independent Director
• Thomas Thomas,
  Director
• Gabrielle Silver,
  Director
• Ann MacDougall,
  Director
• Aziz Mottiwala,
  Chief Commercial Officer
• Rahsaan Thompson,
  General Counsel
• Phil Skolnick,
  Chief Scientific Officer
• Arvind Agrawal,
  Executive Vice President - Medical Affairs
• David O'Toole,
  Chief Financial Officer
• Matthew R. Ruth,
  Chief Commercial Officer
• Dr. Mark Heath Ellison Ph.D.,
  Chief Devel. Officer
• Brian Gorman,
  EVP Corp. Devel. & Gen. Counsel
• Ben Atkins,
  VP of Communications & Investor Relations
• Matthew R. Ruth,
  Chief Commercial Officer
• Ronald W Kaiser,
  Director
• Melvin Iii Wesley,
  Chief Financial Officer
• William F Stasior,
  Director
• Steven G Finn,
  Director
• Joseph W Kuhn,
  VP & Chief Financial Officer
• Alain J Cohen,
  President & Chief Tech Officer
• Marc A Cohen,
  Chairman, CEO, Treas, & Sec
• Brian Gorman,
  
• Mark Jason Heath Ellison,
  Chief Development Officer
• Masuoka K. Lorianne,
  Director